-
Je něco špatně v tomto záznamu ?
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022
C. Garbe, T. Amaral, K. Peris, A. Hauschild, P. Arenberger, N. Basset-Seguin, L. Bastholt, V. Bataille, V. Del Marmol, B. Dréno, MC. Fargnoli, AM. Forsea, JJ. Grob, C. Höller, R. Kaufmann, N. Kelleners-Smeets, A. Lallas, C. Lebbé, B. Lytvynenko,...
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, přehledy, práce podpořená grantem
- MeSH
- konsensus MeSH
- lidé MeSH
- lokální recidiva nádoru patologie MeSH
- melanom * diagnóza patologie terapie MeSH
- nádory kůže * diagnóza patologie terapie MeSH
- PET/CT MeSH
- staging nádorů MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumor and causes 90% of skin cancer mortality. A unique collaboration of multi-disciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC) was formed to make recommendations on CM diagnosis and treatment, based on systematic literature reviews and the experts' experience. The diagnosis of melanoma can be made clinically and shall always be confirmed with dermatoscopy. If a melanoma is suspected, a histopathological examination is always required. Sequential digital dermatoscopy and full body photography can be used in high-risk patients to improve the detection of early melanoma. Where available, confocal reflectance microscopy can also improve clinical diagnosis in special cases. Melanoma shall be classified according to the 8th version of the American Joint Committee on Cancer classification. Thin melanomas up to 0.8 mm tumor thickness do not require further imaging diagnostics. From stage IB onwards, examinations with lymph node sonography are recommended, but no further imaging examinations. From stage IIC onwards whole-body examinations with computed tomography (CT) or positron emission tomography CT (PET-CT) in combination with brain magnetic resonance imaging are recommended. From stage III and higher, mutation testing is recommended, particularly for BRAF V600 mutation. It is important to provide a structured follow-up to detect relapses and secondary primary melanomas as early as possible. There is no evidence to define the frequency and extent of examinations. A stage-based follow-up scheme is proposed which, according to the experience of the guideline group, covers the optimal requirements, but further studies may be considered. This guideline is valid until the end of 2024.
1st Department of Dermatology Aristotle University Thessaloniki Greece
Center for Dermatooncology Department of Dermatology Eberhard Karls University Tuebingen Germany
Department of Dermatology Erasme Hospital Université Libre de Bruxelles Brussels Belgium
Department of Dermatology Maastricht University Medical Center Maastricht the Netherlands
Department of Dermatology Medical University of Vienna Austria
Department of Dermatology University Hospital Schleswig Holstein Campus Kiel Kiel Germany
Department of Dermatovenereology 3rd Faculty of Medicine Charles University Prague Czech Republic
Department of Oncology Odense University Hospital Denmark
Dermatology Clinic Maggiore Hospital University of Trieste Trieste Italy
Dermatology Department CHU Nantes CIC 1413 CRCINA University Nantes Nantes France
Dermatology Unit University of Modena and Reggio Emilia Modena Italy
Fondazione Policlinico Universitario A Gemelli IRCCS Rome Italy
Institute of Dermatology Università Cattolica Rome Italy
Medical and Surgical Dermatology Service Hospital Universitario Virgen Macarena Sevilla Spain
Melanoma Unit Department of Dermatology Hospital Clinic IDIBAPS Barcelona Spain
Mount Vernon Cancer Centre Northwood United Kingdom
Shupyk National Medical Academy of Postgraduate Education Kiev Ukraine
The University of Manchester Oxford Rd Manchester M13 9PL UK
Université Paris Cite AP HP Department of Dermatology INSERM U 976 Hôpital Saint Louis Paris France
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22017881
- 003
- CZ-PrNML
- 005
- 20220804134435.0
- 007
- ta
- 008
- 220720s2022 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejca.2022.03.008 $2 doi
- 035 __
- $a (PubMed)35570085
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Garbe, Claus $u Center for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany. Electronic address: claus.garbe@med.uni-tuebingen.de
- 245 10
- $a European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022 / $c C. Garbe, T. Amaral, K. Peris, A. Hauschild, P. Arenberger, N. Basset-Seguin, L. Bastholt, V. Bataille, V. Del Marmol, B. Dréno, MC. Fargnoli, AM. Forsea, JJ. Grob, C. Höller, R. Kaufmann, N. Kelleners-Smeets, A. Lallas, C. Lebbé, B. Lytvynenko, J. Malvehy, D. Moreno-Ramirez, P. Nathan, G. Pellacani, P. Saiag, AJ. Stratigos, ACJ. Van Akkooi, R. Vieira, I. Zalaudek, P. Lorigan, European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC)
- 520 9_
- $a Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumor and causes 90% of skin cancer mortality. A unique collaboration of multi-disciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC) was formed to make recommendations on CM diagnosis and treatment, based on systematic literature reviews and the experts' experience. The diagnosis of melanoma can be made clinically and shall always be confirmed with dermatoscopy. If a melanoma is suspected, a histopathological examination is always required. Sequential digital dermatoscopy and full body photography can be used in high-risk patients to improve the detection of early melanoma. Where available, confocal reflectance microscopy can also improve clinical diagnosis in special cases. Melanoma shall be classified according to the 8th version of the American Joint Committee on Cancer classification. Thin melanomas up to 0.8 mm tumor thickness do not require further imaging diagnostics. From stage IB onwards, examinations with lymph node sonography are recommended, but no further imaging examinations. From stage IIC onwards whole-body examinations with computed tomography (CT) or positron emission tomography CT (PET-CT) in combination with brain magnetic resonance imaging are recommended. From stage III and higher, mutation testing is recommended, particularly for BRAF V600 mutation. It is important to provide a structured follow-up to detect relapses and secondary primary melanomas as early as possible. There is no evidence to define the frequency and extent of examinations. A stage-based follow-up scheme is proposed which, according to the experience of the guideline group, covers the optimal requirements, but further studies may be considered. This guideline is valid until the end of 2024.
- 650 _2
- $a konsensus $7 D032921
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a melanom $x diagnóza $x patologie $x terapie $7 D008545
- 650 _2
- $a lokální recidiva nádoru $x patologie $7 D009364
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a PET/CT $7 D000072078
- 650 12
- $a nádory kůže $x diagnóza $x patologie $x terapie $7 D012878
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Amaral, Teresa $u Center for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany
- 700 1_
- $a Peris, Ketty $u Institute of Dermatology, Università Cattolica, Rome, Italy; Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy
- 700 1_
- $a Hauschild, Axel $u Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany
- 700 1_
- $a Arenberger, Petr $u Department of Dermatovenereology, Third Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Basset-Seguin, Nicole $u Université Paris Cite, AP-HP Department of Dermatology INSERM U 976 Hôpital Saint Louis Paris France
- 700 1_
- $a Bastholt, Lars $u Department of Oncology, Odense University Hospital, Denmark
- 700 1_
- $a Bataille, Veronique $u Twin Research and Genetic Epidemiology Unit, School of Basic & Medical Biosciences, King's College London, London, SE1 7EH, UK
- 700 1_
- $a Del Marmol, Veronique $u Department of Dermatology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
- 700 1_
- $a Dréno, Brigitte $u Dermatology Department, CHU Nantes, CIC 1413, CRCINA, University Nantes, Nantes, France
- 700 1_
- $a Fargnoli, Maria C $u Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy
- 700 1_
- $a Forsea, Ana-Maria $u Dermatology Department, Elias University Hospital, Carol Davila University of Medicine and Pharmacy Bucharest, Romania
- 700 1_
- $a Grob, Jean-Jacques $u University Department of Dermatology, Marseille, France
- 700 1_
- $a Höller, Christoph $u Department of Dermatology, Medical University of Vienna, Austria
- 700 1_
- $a Kaufmann, Roland $u Department of Dermatology, Venereology and Allergology, Frankfurt University Hospital, Frankfurt, Germany
- 700 1_
- $a Kelleners-Smeets, Nicole $u Department of Dermatology, Maastricht University Medical Center+, Maastricht, the Netherlands
- 700 1_
- $a Lallas, Aimilios $u First Department of Dermatology, Aristotle University, Thessaloniki, Greece
- 700 1_
- $a Lebbé, Celeste $u Université Paris Cite, AP-HP Department of Dermatology INSERM U 976 Hôpital Saint Louis Paris France
- 700 1_
- $a Lytvynenko, Bohdan $u Shupyk National Medical Academy of Postgraduate Education, Kiev, Ukraine
- 700 1_
- $a Malvehy, Josep $u Melanoma Unit, Department of Dermatology, Hospital Clinic, IDIBAPS, Barcelona, Spain
- 700 1_
- $a Moreno-Ramirez, David $u Medical-&-Surgical Dermatology Service, Hospital Universitario Virgen Macarena, Sevilla, Spain
- 700 1_
- $a Nathan, Paul $u Mount-Vernon Cancer Centre, Northwood United Kingdom
- 700 1_
- $a Pellacani, Giovanni $u Dermatology Unit, University of Modena and Reggio Emilia, Modena, Italy
- 700 1_
- $a Saiag, Philippe $u University Department of Dermatology, Université de Versailles-Saint Quentin en Yvelines, APHP, Boulogne, France
- 700 1_
- $a Stratigos, Alexander J $u 1st Department of Dermatology, University of Athens School of Medicine, Andreas Sygros Hospital, Athens, Greece
- 700 1_
- $a Van Akkooi, Alexander C J $u Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia
- 700 1_
- $a Vieira, Ricardo $u Department of Dermatology and Venereology, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal
- 700 1_
- $a Zalaudek, Iris $u Dermatology Clinic, Maggiore Hospital, University of Trieste, Trieste, Italy
- 700 1_
- $a Lorigan, Paul $u The University of Manchester, Oxford Rd, Manchester, M13 9PL, UK
- 710 2_
- $a European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC)
- 773 0_
- $w MED00009626 $t European journal of cancer (Oxford, England : 1990) $x 1879-0852 $g Roč. 170, č. - (2022), s. 236-255
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35570085 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804134429 $b ABA008
- 999 __
- $a ok $b bmc $g 1821802 $s 1169124
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 170 $c - $d 236-255 $e 20220512 $i 1879-0852 $m European journal of cancer $n Eur J Cancer $x MED00009626
- LZP __
- $a Pubmed-20220720
